 Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: The effect of DNA damage repair status on the activity of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer

Eur J Cancer: The effect of DNA damage repair status on the activity of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

psa test prep

eating cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Previous studies have shown that Cabazitaxel can improve the overall survival (OS) of patients with metastatic castration-resistant prostate cancer (mCRPC) after treatment failure with abiraterone/enzalutamide and docetaxel, although The benefits of the presence of DNA damage repair (DDR) defects are unclear

This study aims to clarify the effect of DNA damage repair status on the efficacy of cabazitaxel in the treatment of mCRPC patients

This is a prospective multicenter study that recruited mCRPC patients treated with cabazitaxel who underwent DDR tumor tissue analysis

Prognosis analysis of patients grouped by DDR status according to tissue analysis

Among the 190 patients with organized sequencing data (95 DDR+, 95 DDR-), the proportions of patients in the DDR+ and DDR- groups who obtained PSA50 after cabazitaxel treatment were 32% (29/92) and 36%, respectively (33/92; p=0.

p=0.

Prognostic analysis of patients grouped by liquid biopsy DDR status

Similar results were observed in the liquid biopsy cohort (DDR+, n=63)

In summary, the results of the study show that the existence of DNS damage repair defects does not affect the effect of cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer , but cabazitaxel is used in patients who have previously received PARPi treatment.

The presence or absence of DNS damage repair defects does not affect the effect of cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer.

Original source:

Aldea Mihaela,Lam Laurent,Orillard Emeline et al.

Cabazitaxel activity in men with metastatic castration- resistant prostate cancer with and without DNA damage repair defects

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.